New Data Reinforce Benefits of TomoTherapy(R) Platform for Mainstream Radiation Therapy Treatment Indications
Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control withReduced Toxicities
SUNNYVALE, Calif., May 11, 2017 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies contin... Devices, Oncology Accuray, TomoTherapy, radiotherapy, IMRT
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Intensity-Modulated Radiation Therapy | Marketing | Pharmaceuticals | Radiation Therapy | Study | Toxicology